Pure Global
NCT06383468

A Phase III Study to Evaluate the Efficacy and Safety of AK120 in Patients With Moderate to Severe Atopic Dermatitis

a Randomized Double-blind, Placebo-controlled, Multicenter Phase III Clinical Study to Evaluate the Efficacy and Safety of AK120 in the Treatment of Patients With Moderate to Severe Atopic Dermatitis
Akeso·Phase 3·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Atopic Dermatitis
Drug/Device/Intervention
AK120
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Akeso
Location
Beijing,Beijing,Beijing,Beijing,Beijing,Chongqing,Chongqing,Fuzhou,Xiamen,Guangzhou,Guangzhou,Guangzhou,Guangzhou,Guangzhou,Guangzhou,Shaoguan,Shunde,Zhanjiang,Guiyang,Haikou,Haikou,Haikou,Chengde,Xin, China
Timeline & enrollment
Phase
Phase 3
Start date
Apr 30, 2024
End date
Jan 30, 2026
Enrollment
420 participants
Primary outcome

Percentage of subjects who achieved (Eczema Area and Severity Index) EASI-75

Summary

This is a randomized double-blind, placebo-controlled, multicenter phase III clinical study
 evaluating the efficacy and safety of AK120 injection in the treatment of patients with
 moderate to severe atopic dermatitis.

ICD-10 classifications
Atopic dermatitisAtopic dermatitis, unspecifiedOther atopic dermatitisAcute atopic conjunctivitisAllergic contact dermatitis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06383468
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06383468 through Pure Global AI's free database. This Phase 3 trial is sponsored by Akeso and is currently Recruiting. The study focuses on Atopic Dermatitis. Target enrollment is 420 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.